GlassScriptPhysician profile
Allen L Solomon
NPI 1922083971
$3,722.59
in general payments reported to CMS, 2019-2025
27 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $266 · 2021: $192 · 2022: $808 · 2023: $634 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $678.07 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $413.53 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $314.86 | 2019-2022 | |
| Allergan, INC. | $220.44 | 2019-2020 | |
| Corium, LLC | $217.23 | 2022-2023 | Adlarity, Azstarys |
| Lundbeck LLC | $202.53 | 2019-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $169.37 | 2019-2023 | Uzedy |
| Supernus Pharmaceuticals, INC. | $162.81 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $138.47 | 2019-2023 | Trintellix |
| Neos Therapeutics, LP | $128.97 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $125.30 | 2019-2022 | |
| Zimvie INC. | $124.00 | 2023 | |
| Avanir Pharmaceuticals, INC. | $108.59 | 2019-2022 | |
| Alkermes, INC. | $93.43 | 2022-2023 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $82.64 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.63 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $62.00 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.74 | 2021-2022 | |
| Almatica Pharma LLC | $53.43 | 2022-2023 | Loreev Xr |
| Arbor Pharmaceuticals, INC. | $51.76 | 2019 | |
| Abbvie INC. | $50.52 | 2021-2022 | |
| Adlon Therapeutics L.P. | $43.54 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $42.52 | 2019 | |
| Shire North American Group INC | $42.36 | 2019 | |
| Bausch Health US, LLC | $29.56 | 2019-2020 | |
| Alpha Cognition USA, INC. | $21.92 | 2025 | Zunveyl |
| Idorsia Pharmaceuticals US INC | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.